What is the differential diagnosis and recommended next steps for a 39-year-old man with a low white blood cell count, elevated red blood cell count, hemoglobin, hematocrit, low platelet count, and increased mean platelet volume on a complete blood count?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Differential Diagnosis and Next Steps

This CBC pattern—elevated RBC/Hgb with thrombocytopenia and borderline leukopenia—raises concern for a myeloproliferative neoplasm (MPN), specifically early primary myelofibrosis (PMF) or polycythemia vera (PV), and requires immediate JAK2, CALR, and MPL mutation testing along with bone marrow biopsy.

Key CBC Pattern Analysis

The constellation of findings is highly suggestive of a clonal myeloid disorder:

  • Elevated RBC (5.77) and Hemoglobin (16.4): While not meeting strict PV criteria (Hgb >18.5 g/dL for men per WHO 2016), this represents relative erythrocytosis 1
  • Thrombocytopenia (120 × 10⁹/L) with elevated MPV (11.4): This combination is particularly concerning. Elevated MPV with low platelet count strongly suggests a hyperdestructive or myeloproliferative process 2
  • Borderline leukopenia (4.17): Unusual in isolation but can occur in early MPN

Most Likely Diagnoses

Primary Consideration: Pre-fibrotic/Early Primary Myelofibrosis

This pattern is most consistent with pre-PMF because:

  • The combination of erythrocytosis with thrombocytopenia is atypical for classic PV (which typically shows thrombocytosis)
  • Elevated MPV with low platelets suggests abnormal megakaryopoiesis, a hallmark of PMF 3
  • Early PMF can present with hypercellular marrow and variable cytopenias before overt fibrosis develops

Secondary Consideration: Atypical Polycythemia Vera

Less likely but possible if:

  • This represents evolving PV with spent phase features
  • However, PV typically shows elevated WBC and platelets initially 1

Alternative Diagnoses to Exclude

  • Spurious results: EDTA-dependent platelet clumping can cause falsely low platelet counts 4. However, elevated MPV argues against this
  • Secondary erythrocytosis with unrelated thrombocytopenia: Less likely given the MPV elevation
  • Hypersplenism: Could explain bicytopenia but wouldn't typically elevate RBC count

Immediate Diagnostic Workup

First-Line Testing (Order Immediately):

  1. Molecular testing 1:

    • JAK2 V617F mutation (present in ~60% of PMF, 95% of PV)
    • CALR mutations (present in ~25% of PMF)
    • MPL mutations (present in ~8% of PMF)

  2. Peripheral blood smear review:

    • Look for leukoerythroblastosis (immature WBCs and nucleated RBCs)
    • Assess for teardrop cells (dacrocytes)—characteristic of myelofibrosis
    • Confirm platelet count and evaluate platelet morphology
    • Rule out platelet clumping causing spurious thrombocytopenia

  3. Serum erythropoietin level:

    • Should be low/normal in PV (minor criterion) 3, 1
    • May be elevated in secondary erythrocytosis

  4. LDH and uric acid:

    • Elevated in PMF (minor criterion) 3, 1

Second-Line Testing (Based on Initial Results):

  1. Bone marrow biopsy with reticulin staining 3:

    • Essential for diagnosis—distinguishes pre-PMF from PV and ET
    • Pre-PMF shows: megakaryocyte proliferation and atypia, hypercellularity, minimal/no reticulin fibrosis (grade 0-1)
    • PV shows: trilineage myeloproliferation with pleomorphic megakaryocytes
    • Assess reticulin fibrosis grade (0-3 scale) 3

  2. Abdominal ultrasound:

    • Assess for splenomegaly (minor criterion for PMF) 1

Clinical Pitfalls to Avoid

  • Don't dismiss as "borderline normal": This subtle pattern can represent early MPN that will progress
  • Don't assume spurious platelet count without confirming: Repeat CBC in citrate tube if EDTA-dependent clumping suspected, but elevated MPV makes this less likely 4
  • Don't delay bone marrow biopsy: Histology is critical for distinguishing pre-PMF from other MPNs, as molecular markers overlap 3
  • Don't order red cell mass measurement routinely: The 2016 WHO criteria eliminated this requirement for PV diagnosis 1

Risk Stratification Implications

If PMF is confirmed, immediate prognostic scoring is needed:

  • Age, constitutional symptoms, hemoglobin, WBC count, peripheral blasts, and karyotype determine risk category
  • This guides treatment intensity (observation vs. JAK inhibitors vs. transplant consideration)

Why This Matters for Morbidity/Mortality

Early diagnosis is critical: MPNs carry thrombotic risk (stroke, MI), risk of progression to acute leukemia (10-20% for PMF), and significantly impact quality of life through symptoms and potential transformation. Identifying the specific MPN subtype determines whether the patient needs cytoreduction, antiplatelet therapy, or consideration for allogeneic stem cell transplant—the only curative option for PMF.

References

Related Questions

What is the significance of a white blood cell count of 3.7 ×10⁹/L, red blood cell count of 3.60 ×10¹²/L, hemoglobin 12.1 g/dL, and hematocrit 35.4%, and what work‑up and management are indicated?
In a 39-year-old male with a mildly low white blood cell count (4.13 ×10⁹/L), normal red blood cell count (5.57 ×10¹²/L), slightly elevated mean platelet volume (10.6 fL) and otherwise normal complete blood count and comprehensive metabolic panel, what is the appropriate management?
How should I interpret a CBC with hemoglobin 10.2 g/dL, hematocrit 34.5 %, MCV 73.2 fL, MCH 21.7 pg, MCHC 29.6 g/dL, normal white‑cell count, and platelet count 87 ×10⁹/L?
How should I interpret a red blood cell count of 5.29 ×10⁶/µL, a platelet count of 132 ×10³/µL, and a mean platelet volume of 13.1 fL?
What are the management options for a mildly decreased white blood cell (WBC) count?
In a dengue patient with severe lethargy and peripheral oxygen saturation (SpO₂) dropping to 93% after urination, how can the patient be stimulated to become active and how can SpO₂ be increased when there is no pulmonary fluid accumulation?
In a 40‑year‑old patient with multiple low‑flow vascular malformations (hemangiomas) in the abdomen, gluteal region, chest, a resolved neck lesion, an interatrial septal aneurysm, a subcapsular splenic cyst, and a family history of cervical cancer, what diagnostic work‑up should be performed, including recommendations for genetic testing and specific imaging and laboratory studies?
What is the appropriate propofol infusion dosage for pediatric patients undergoing surgery with inhalational anesthesia without a muscle relaxant?
What is the normal hemoglobin A1c range for a healthy 3-year-old female?
In a 17‑year‑old patient taking oxcarbazepine (Trileptal) for challenging behaviors who continues to have problematic behaviors, what medication should be added and what baseline laboratory studies should be ordered?
In a patient with congestive heart failure, renal failure, and fluid overload, can low-dose furosemide (Lasix) be used for treatment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.